498.43
-23.82 (-4.56%)
| Previous Close | 522.25 |
| Open | 523.04 |
| Volume | 2,216,132 |
| Avg. Volume (3M) | 1,465,783 |
| Market Cap | 126,504,239,104 |
| Price / Earnings (TTM) | 30.96 |
| Price / Earnings (Forward) | 27.78 |
| Price / Sales | 11.15 |
| Price / Book | 6.94 |
| 52 Weeks Range | |
| Earnings Date | 3 Aug 2026 |
| Profit Margin | -8.91% |
| Operating Margin (TTM) | 37.22% |
| Diluted EPS (TTM) | -3.80 |
| Quarterly Revenue Growth (YOY) | 3.00% |
| Quarterly Earnings Growth (YOY) | -41.20% |
| Total Debt/Equity (MRQ) | 10.00% |
| Current Ratio (MRQ) | 2.65 |
| Operating Cash Flow (TTM) | -980.30 M |
| Levered Free Cash Flow (TTM) | 2.63 B |
| Return on Assets (TTM) | 11.77% |
| Return on Equity (TTM) | -5.64% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Vertex Pharmaceuticals Incorpor | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | -3.5 |
| Price Volatility | -0.5 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 4.0 |
| Average | 0.38 |
|
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Large Value |
| % Held by Insiders | 0.15% |
| % Held by Institutions | 97.64% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BOZIC CARMEN | - | 491.34 | -596 | -292,839 |
| LIU JOY | - | 498.01 | -828 | -412,352 |
| MCKECHNIE DUNCAN | - | 528.04 | -1,541 | -813,710 |
| TATSIS OURANIA | - | 528.04 | -1,500 | -792,060 |
| Aggregate Net Quantity | -4,465 | |||
| Aggregate Net Value ($) | -2,310,961 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 511.36 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| MCKECHNIE DUNCAN | Officer | 02 Jul 2026 | Automatic sell (-) | 1,541 | 528.04 | 813,710 |
| TATSIS OURANIA | Officer | 02 Jul 2026 | Automatic sell (-) | 1,500 | 528.04 | 792,060 |
| LIU JOY | Officer | 01 Jul 2026 | Automatic sell (-) | 828 | 498.01 | 412,352 |
| BOZIC CARMEN | Officer | 26 Jun 2026 | Automatic sell (-) | 596 | 491.34 | 292,839 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |